One of the most important transformations in the pharmaceutical industry over the next decade is the ability to modify genes or expression and go after any target, Cargene Biopharma Inc. CEO Kathy He told BioWorld, explaining that small molecules and large molecules can only go after 15% of the known targets. But the technology platform of short-interfering RNA (siRNA) opens a huge opportunity to make those inaccessible targets available, she said.
When oxygen levels of the intestine increase, the appropriate hypoxic conditions for intestinal microbiota are lost. This state may be caused by immune-mediated malfunction of the intestinal epithelium. By controlling oxygen levels, the imbalance in the intestinal microbiome (dysbiosis) can be reduced.
Boston Immune Technologies and Therapeutics Inc. (BITT) has announced progress using its Domab platform. Two Domab CD40 antagonists, BITT-CD4D11 and BITT-CD4F10, have completed discovery and optimization and a final candidate is being selected for IND-enabling steps.
Researchers from Yale School of Medicine, along with Helsinki University Hospital and University of Helsinki, have reported data from a study that aimed to assess the effects of a common variant in hydroxysteroid 17-β dehydrogenase 13 (HSD17B13 rs72613567-A) in the liver.
Two papers in the Feb. 8, 2023, issue of Cell Host & Microbe have reported new insights into the relationship between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and alterations in the gut microbiome, and how those relationships change over time. A reliable way to diagnose ME/CFS would be a huge step forward for the study of ME/CFS. Currently, the condition is diagnosed purely by symptoms, which are assessed via questionnaire.
Insulin resistance in type 2 diabetes (T2DM) is associated with hepatosteatosis and the development of nonalcoholic fatty liver disease (NAFLD), with the pathogenesis of NAFLD being complex and involving the crosstalk between the liver and white adipose tissue (WAT).
Rise Therapeutics LLC has received FDA clearance for its IND application to proceed with a phase I trial of R-3750, a synthetic biology-based cellular immunotherapy being developed for the treatment of inflammatory bowel disease. The phase I trial will enroll patients with mild to moderate ulcerative.
Hepatocellular death is an important process for liver homoeostasis by elimination and replacement of impaired hepatocytes. Hepatocellular death occurs little under normal conditions in the healthy liver, and it plays a key role as a trigger of liver regeneration; meanwhile, hepatic steatosis increases hepatocellular death during liver regeneration, exacerbating both acute and chronic liver damage.
RSS
